Plain-English translation of NCT07325630 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether a new immunotherapy medication called IBI363, combined with standard chemotherapy drugs, can help shrink advanced stomach cancer before surgery. The study focuses on patients whose cancer cells have a specific genetic feature (being MHC-II negative). Researchers want to see if this medication, given before surgery along with chemotherapy, is safe and effective.
Advanced stomach cancer is difficult to treat, and surgery alone often isn't enough to cure it. Doctors use chemotherapy before surgery to shrink tumors and improve outcomes. This trial exists to see whether adding this new immunotherapy to standard chemotherapy can help patients with this particular type of stomach cancer do even better.
You likely qualify if…
You likely don't qualify if…
You would receive the new immunotherapy medication IBI363 combined with one of two standard chemotherapy regimens (either XELOX or SOX) as neoadjuvant treatment—meaning before your planned stomach surgery. This is a single-center study at Zhejiang Cancer Hospital, so all visits and treatment would be at that location. After completing the chemotherapy and immunotherapy, you would then proceed to surgery as planned. The study will monitor your safety and how well the treatment works.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
China
Phase
Testing effectiveness
Sponsor
Zhejiang Cancer Hospital
Enrollment target
~60 participants
Started
November 2025
Primary completion
May 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 75 Years
Last updated on clinicaltrials.gov in January 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Xiangdong Cheng
Zhejiang Cancer Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.